Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731

27 Aug 2020

Abstract excerpt

s from 1.84 μM to 7.3 μM. Mechanism-of-action studies indicated that ABI-H0731 is a direct-acting antiviral that targets HBV core protein, preventing HBV pregenomic RNA (pgRNA) encapsidation and subsequent DNA replication. The combination of ABI-H0731 with entecavir appears to decrease viral DNA faster and deeper than nucleoside/nucleotide analogue (NrtI) therapy alone. In addition, ABI-H0731 disrupts incoming...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Hepatitis C virus research
Share to Liver Disease Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32868329
DOI: 10.1128/aac.01463-20

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731PMID 32868329Read ↗

HBV cccDNA─A Culprit and Stumbling Block for the Hepatitis B Virus Infection: Its Presence in Hepatocytes Perplexed the Possible Mission for a Functional CureSemantic proximity Read ↗

Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA.Semantic proximity Read ↗

Pharmacology Update for the Treatment of Hepatitis C Virus.Semantic proximity Read ↗

Preclinical and clinical antiviral characterization of AB-836, a potent capsid assembly modulator against hepatitis B virus.Semantic proximity Read ↗

The Intrinsically Disordered Region of HBx and Virus–Host Interactions: Uncovering New Therapeutic Approaches for HBV and CancerSemantic proximity Read ↗

Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents.Semantic proximity Read ↗

The progress of molecules and strategies for the treatment of HBV infectionSemantic proximity Read ↗

Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA TherapeuticSemantic proximity Read ↗

GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.Semantic proximity Read ↗

Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus InfectionsSemantic proximity Read ↗

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B InfectionSemantic proximity Read ↗

Structure-Activity Relationships in the Development of Allosteric Hepatitis C Virus RNA-Dependent RNA Polymerase Inhibitors: Ten Years of ResearchSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.